Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
63.92
+0.49 (0.77%)
Oct 15, 2026, 4:00 PM EDT - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $109.4. The average 1-year stock price forecast is 71.15% higher than the current stock price, while the lowest is $85 (+32.98%) and the highest is $146 (+128.41%).
Price Target: $109.4 (+71.15%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 13 | 13 | 13 | 13 | 13 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 3 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 22 | 22 | 22 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $113 | Buy | Maintains | $113 | +76.78% | Oct 15, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 14, 2026 |
| UBS | UBS | Buy Reiterates $115 → $104 | Buy | Reiterates | $115 → $104 | +62.70% | Oct 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $140 | Buy | Reiterates | $140 | +119.02% | Oct 13, 2026 |
| Needham | Needham | Buy Maintains $112 | Buy | Maintains | $112 | +75.22% | Oct 5, 2026 |
Financial Forecast
Revenue This Year
151.84M
from 88.04M
Increased by 72.47%
Revenue Next Year
424.31M
from 151.84M
Increased by 179.45%
EPS This Year
-5.94
from -6.54
EPS Next Year
-4.44
from -5.94
EPS and Forward PE are based on non-GAAP adjusted numbers.